Key result
Viral vectors show therapeutic potential for heart failure and ischemia despite immunogenicity and tropism hurdles.
This review outlines the current state of cardiovascular gene therapy, detailing potential targets such as heart failure and restenosis, and evaluating viral vectors like adenovirus and AAV for clinical application.
Answers are grounded in this paper and cite their sources.
Viral vector gene therapy remains investigational for heart failure and ischemia; leaves open optimization of adenovirus and AAV to overcome immunogenicity and tropism.
Cardiovascular disease represents the most common cause of mortality in the developed world but, despite two decades of promising pre-clinical research and numerous clinical trials, cardiovascular gene transfer has so far failed to demonstrate convincing benefits in the clinical setting. In this review we discuss the various targets which may be suitable for cardiovascular gene therapy and the viral vectors which have to date shown the most potential for clinical use. We conclude with a summary of the current state of clinical cardiovascular gene therapy and the key trials which are ongoing.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2010) conducted a review in Cardiovascular disease. Viral vectors for cardiovascular gene therapy was evaluated. Viral vectors, particularly adenovirus and adeno-associated virus, show potential for cardiovascular gene therapy targeting heart failure and ischemia, despite challenges with immunogenicity and tropism.
Synapse has enriched 10 related papers. Consider them for comparative context: